Newswise — In three recent publications in Molecular Psychiatry, Brain and JAMA Neurology researchers from the University of Gothenburg provide convincing evidence that an in-house developed blood test for Alzheimer’s disease can detect the disease early and track its course, which has major implications for a potential use in clinical practice and treatment trials.
“This is an extremely dynamic research field right now, thanks to the technological development and seminal scientific progress in the past years. The dream scenario is to have a blood test for the early detection and screening of Alzheimer’s disease up and running. That would give significantly more people in the world access to testing and future treatments”, says Michael Schöll, associate professor and one of the senior authors.
After decades of research, we now know that Alzheimer’s disease-related…
